Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

Core Viewpoint - Humacyte, Inc. is advancing its biotechnology platform focused on universally implantable, bioengineered human tissues, with significant developments in clinical trials and regulatory approvals [1][3]. Company Overview - Humacyte, Inc. (Nasdaq: HUMA) is a biotechnology platform company that develops acellular tissues aimed at treating various diseases and chronic conditions [3]. - The company is currently focused on its acellular tissue engineered vessels (ATEVs), which are in late-stage clinical trials for multiple vascular applications, including vascular trauma repair and hemodialysis access [3]. - A Biologics License Application for the ATEV in vascular trauma was approved by the FDA in December 2024, marking a significant milestone for the company [3]. Upcoming Events - Laura Niklason, M.D., Ph.D., the Founder and CEO of Humacyte, will present at the TD Cowen 45 Annual Health Care Conference on March 4, 2025, at 3:10 p.m. EST [1][2]. - The presentation will be available via webcast, with a replay accessible on Humacyte's website [2]. Product Development - Humacyte's 6mm ATEV for AV access in hemodialysis is notable for being the first to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, along with Fast Track designation [3]. - The ATEV has also received priority designation for vascular trauma treatment from the U.S. Secretary of Defense [3]. - Preclinical development is ongoing for additional applications, including coronary artery bypass grafts and treatment of type 1 diabetes [3].